P R O H O S T   O n l i n e The Newsletter of Biotechnology Insight and Investment
Eye on the News [ Home | Contents | Search | Next | Previous | Up ]

AVI JOINS THE RUSSELL 3000

interracialsexfest xndx

Date: 12 Dec 2007
Time: 14:42:08

Comments

http://www.interracialsexfest.com/?a=975445 http://www.justlegalbabes.com/?a=975445 http://www.kinkymaturesluts.com/?a=975445 http://www.kuntfu.com/?a=975445 http://www.latinasex.com/?a=975445 http://www.lipsticklesbo.com/?a=975445 http://www.milfhunter.com/?id=chikenn http://www.manhunter.com/?a=975445

Date: 27 Jun 2001
Time: 14:53:32

Comments

PORTLAND, Ore.--(BW HealthWire)--June 26, 2001--AVI BioPharma, Inc. (AVII) announced today that it is poised to join the prestigious Russell 3000® Index, a financial measure of the most successful large cap and small cap public companies that is used as a benchmark for investors.

AVI was added to the preliminary index list June 8 and is expected to be added to the index July 9 as part of Frank Russell Co.'s annual reconstitution of its U.S. equity indices. It is a financial landmark for companies to be selected for the list because it is determined strictly by market capitalization rankings and style attributes, rather than by subjective opinion or committee.

The Russell 3000 Index represents 98 percent of the U.S. equity market. It measures the performance of the 3,000 largest U.S. companies based on total market capitalization and serves as a model for both passive and active investment strategies. It includes the 1,000 largest large cap companies as well as the top 2,000 small cap companies. The final membership lists for the Russell indices will be posted on the Russell web site July 9. The Russell 3000 stocks are selected from the New York Stock Exchange, American Stock Exchange, and the NASDAQ.

``AVI's debut on the Russell 3000 Index reflects our significant growth,'' said Alan Timmins, President and Chief Operating Officer of AVI BioPharma. ``We're pleased to be part of such a successful peer group.''

Frank Russell Company, one of the world's leading investment management and advisory firms, provides investment advice and funds to institutional investors in more than 30 countries. Russell's investment business employs a manager of managers approach and has more than $66 billion in assets under management. The company has retainer consulting relationships with clients representing more than U.S. $1 trillion worldwide. Russell is a subsidiary of The Northwestern Mutual Life Insurance Company. Russell is headquartered in Tacoma, Wash. and has offices worldwide.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: cancer immunotherapy and gene-targeted drugs. Its lead clinical agent, AVICINE(TM), a therapeutic cancer vaccine, has completed enrollment in a Phase II trial in pancreatic cancer and is in a Phase III pivotal trial in colorectal cancer. The first application of its NEUGENE compounds, Resten-NG, is designed to treat cancer, cardiovascular restenosis and other cell proliferation disorders by inhibiting the production of a cellular transcription factor, the oncogene c-myc. It is currently in Phase II trial for restenosis and a Phase I/II study for cancer. More information about AVI is available on the Company's web site at http://www.avibio.com.

Safe Harbor

Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of pre-clinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's Securities and Exchange Commission filings.

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Send mail to CompanyWebmaster with questions or comments about this web site. Copyright © 2001 CompanyLongName